BioOrbit tests space-made drug crystals in orbit
UK biotech BioOrbit is testing whether microgravity can help manufacture protein crystals for cancer drugs, showing a quirky but serious overlap between biotech and SpaceTech.
What happened
BioOrbit, a UK biotech startup, launched an experiment to the International Space Station to test whether microgravity can help manufacture protein crystals used in cancer drug development.
The company has also been reported to have raised £9.8M and received a £250k UK Space Agency contract.
Why it matters
Some biological materials behave differently in microgravity. That creates a strange-but-promising question: could space become useful for parts of advanced drug development or manufacturing?
It is early, experimental, and very much in the “let’s see if this actually scales” zone — but that is exactly why it is worth watching.
The signal
The space economy is not only about rockets and satellites. It may also become infrastructure for specialised science, including biotech manufacturing.